ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-03-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: mrigrowthcelltumorcells
  Phrases that lowered it: dosethe studyenrolled inplannedmg
• Sponsor's past termination rate: 24.6% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Maximum age: 120 (lowers risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 93.4% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 27 (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 606 (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 2335 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma NCT03782415 · started 2018 · scored riskier than 94% of active trials completed
• A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma NCT03150862 · started 2017 · scored riskier than 79% of active trials completed
• Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma NCT01849146 · started 2013 · scored riskier than 98% of active trials completed
• BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma NCT00727506 · started 2008 · scored riskier than 62% of active trials completed
• TPI 287 in Patients With Recurrent Glioblastoma Multiforme NCT01113463 · started 2010 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.